MedPath

Frequent Activity Snacks Breaks

Not Applicable
Completed
Conditions
Obesity
Sedentary Lifestyle
Insulin Resistance
Registration Number
NCT03083587
Lead Sponsor
Karolinska Institutet
Brief Summary

There is a growing health burden in Sweden and Europe arising from the interrelated sequelae of metabolic disorders comprising impaired glucose tolerance (IGT), obesity and T2DM. Obesity and inactivity are the main drivers of IGT and T2DM and are responsible for up to 8% of health costs and 13% of deaths in Europe, with the risk of co-morbidities rising in parallel with increasing body weight. IGT and T2DM are the paradigm of inactivity-related disorders: the majority of people who have IGT or T2DM are overweight and inactive, with up to 80% being obese. A recent meta-analysis of 42 studies concluded that sedentary time was independently associated with a greater risk of T2D, all-cause mortality, cardiovascular disease incidence and mortality, and cancer incidence and mortality (breast, colon, colorectal, endometrial and epithelial ovarian cancers) (Ann Intern Med. 2015;162:123-32). A recent systematic review of trials published up to April 2014 identified 16 separate studies and concluded that there is considerable evidence of the positive effects of breaking up prolonged sitting time with light-intensity ambulatory physical activity and standing on postprandial metabolic parameters, including glucose, insulin and triglyceride levels (Med Sci Sports Exerc. 2015:47:2053-61). However, to date, all of the published experimental trials describing the beneficial effects of breaking up sitting time on metabolic risk markers have been restricted to acute exposure periods (1-5 days). We will perform a RCT intervention study, which examines the efficacy (clinically relevant responses) and practical implementation of low-impact training in sedentary obese individuals during the day.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Sedentary lifestyle,
  • BMI 30-40 kg/m2
Exclusion Criteria
  • Unable to read Swedish (for informed consent),
  • anticoagulant therapy,
  • unability to perform intervention

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in metabolic health including insulin resistanceChange from baseline and 4 week intervention

Oral glucose tolerance test including baseline glucose and insulin

Secondary Outcome Measures
NameTimeMethod
Changes in gene expressionChange from baseline and 4 week intervention

RNA, mRNA, DNA methylation

Changes in physical activityChange from baseline and 4 week intervention

Objective measures of standing and sitting

Changes at the molecular level in skeletal and fat muscle biopsiesChange from baseline and 4 week intervention

Lipid, protein and metabolites

Changes in plasma glucoseChange from baseline and 4 week intervention

Continuous glucose monitoring

Trial Locations

Locations (1)

Danderyd Hospital

🇸🇪

Stockholm, Sweden

Danderyd Hospital
🇸🇪Stockholm, Sweden

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.